BioCentury | Aug 18, 2020
Product Development

Gilead, Tango expand cancer partnership; plus Roche approval, Novavax COVID-19 efficacy study and G1, Myovant and PTC applications under review

...Virtual Launch”).TARGETSAQP4 – Aquaporin-4CDK4 – Cyclin dependent kinase 4CDK6 – Cyclin dependent kinase 6GNRHR – GnRH/LHRH...
BioCentury | Jul 6, 2020
Product Development

July 6 Quick Takes: Cellectis CAR T trial halted; plus data readouts from Bellus, ObsEva, Idorsia, and more

...years (see “Major Multinationals Open, Close, Open R&D Centers in China” ). Targets GNRHR - GnRH/LHRH...
BioCentury | Jun 24, 2020
Regulation

Myovant eyes third NDA for relugolix after endometriosis readout

...under EMA review. Targets GNRHR - GnRH/LHRH receptor Elizabeth S. Eaton, Staff Writer Relumina (relugolix, TAK-385) Myovant Sciences Ltd. GnRH/LHRH...
BioCentury | Jun 23, 2020
Product Development

June 22 Quick Takes: Invitae acquiring ArcherDX; plus lymphoma approval for Karyopharm, Merck, Nabriva, Myovant, Assembly-AbbVie, Genentech and more

...B gamma BCMA (TNFRSF17; CD269) - Tumor necrosis factor receptor superfamily member 17 GNRHR - GnRH/LHRH...
...AG Myovant Sciences GmbH AbbVie Inc. Assembly Biosciences Inc. Genentech Inc. GlaxoSmithKline plc Innovent Biologics Inc. BeiGene Ltd. Sanofi Regeneron Pharmaceuticals Inc. National Institutes of Health GnRH/LHRH...
BioCentury | Apr 23, 2020
Product Development

April 22 Quick Takes: Accelerated approval for Immunomedics’ Trodelvy; plus BioNTech-Pfizer, AskBio, Astellas, Merck KGaA, oNKo-Gilead, Myovant, Afyx and Sangam

...with uterine fibroids in May 2020. Myovant also submitted an NDA for monotherapy with the GnRH/LHRH...
...Inc. Kite Pharma Inc. BioNTech SE Pfizer Inc. Asklepios BioPharmaceutical Inc. Astellas Pharma Inc. Merck KGaA Myovant Sciences Ltd. Afyx Therapeutics Sangamo Therapeutics Inc. Mogrify Ltd. GnRH/LHRH...
BioCentury | Mar 23, 2020
Product Development

Lilly trial slowdown could include Phase III GI candidate; Syncona among others acknowledging delays

...fibroids, are fully enrolled; data are due on time next quarter. The therapy is a GnRH/LHRH...
...Outbreak” ). Targets GnRH - Gonadotropin-releasing hormone IL23P19 (IL23A) - Interleukin-23 subunit α LHRH - Luteinizing hormone-releasing hormone Paul...
BioCentury | Jan 25, 2020
Targets & Mechanisms

CAR T strategies for cracking the code in solid tumors

...zeste homolog 2 (EZH2) Fibroblast activation protein (FAP) Folate receptor 1 (FOLR1) (FR-alpha) (FOLR) Ganglioside GD2 (GD2) Glypican 2 (GPC2) GnRH/LHRH...
BioCentury | Sep 6, 2019
Company News

Sumitomo Dainippon to bolster pipeline via deal for women's health, urology, rare disease vants for $3B

...$673 million, after shedding $0.53 to $7.51 on Friday. Its lead program is relugolix, a GnRH/LHRH...
...GmbH Roivant Sciences GmbH Sumitomo Dainippon Pharma Co. Ltd. Takeda Pharmaceutical Co. Ltd. Urovant Sciences Ltd. Adrenergic receptor beta 3 (ADRB3) GnRH/LHRH...
BioCentury | Jul 23, 2019
Clinical News

July 23 Clinical Quick Takes: Achillion plans U.S. IND; plus Chiasma, Myovant, Marinus and Merck

...uterine fibroids. The company plans to submit an NDA to FDA by YE19 for the GnRH/LHRH...
...Pharmaceuticals Inc. Chiasma Inc. Marinus Pharmaceuticals Inc. Merck & Co. Inc. Myovant Sciences Ltd. Complement factor D (CFD) (adipsin) GABA A receptor GnRH/LHRH...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...III testing for uterine fibroids and Phase II testing to treat endometriosis. Linzagolix is a GnRH/LHRH...
...hydroxylase (EGLN) IL-33 - Interleukin-33 (NF-HEV) JAK-1 - Janus kinase-1 KRAS - K-Ras LHRH - luteinizing hormone-releasing hormone...
Items per page:
1 - 10 of 494